Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Spinal muscular atrophy type 1 (SMA1) is a progressive, monogenic motor neuron disease with an onset during infancy that results in failure to achieve motor milestones and in death or the need for mechanical ventilation by 2 years of age. We studied functional replacement of the mutated gene encoding survival motor neuron 1 (SMN1) in this disease. METHODS: vg per kilogram). The primary outcome was safety. The secondary outcome was the time until death or the need for permanent ventilatory assistance. In exploratory analyses, we compared scores on the CHOP INTEND (Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders) scale of motor function (ranging from 0 to 64, with higher scores indicating better function) in the two cohorts and motor milestones in the high-dose cohort with scores in studies of the natural history of the disease (historical cohorts). RESULTS: As of the data cutoff on August 7, 2017, all 15 patients were alive and event-free at 20 months of age, as compared with a rate of survival of 8% in a historical cohort. In the high-dose cohort, a rapid increase from baseline in the score on the CHOP INTEND scale followed gene delivery, with an increase of 9.8 points at 1 month and 15.4 points at 3 months, as compared with a decline in this score in a historical cohort. Of the 12 patients who had received the high dose, 11 sat unassisted, 9 rolled over, 11 fed orally and could speak, and 2 walked independently. Elevated serum aminotransferase levels occurred in 4 patients and were attenuated by prednisolone. CONCLUSIONS: In patients with SMA1, a single intravenous infusion of adeno-associated viral vector containing DNA coding for SMN resulted in longer survival, superior achievement of motor milestones, and better motor function than in historical cohorts. Further studies are necessary to confirm the safety and efficacy of this gene therapy. (Funded by AveXis and others; ClinicalTrials.gov number, NCT02122952 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Notably, the FDA has approved AAV for gene replacement therapy in spinal muscular atrophy and congenital blindness, and clinical trials are in progress 58 .”
From The promise and challenge of therapeutic genome editing (2020) · cites this paper as [58]
In the citing paper
“preclinical and clinical studies have demonstrated dose-dependent inflammation, which can reduce efficacy and lead to dose-limiting toxicity (2–8)”
From Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses (2021) · cites this paper as [4]
In the citing paper
“Although neuroimaging is typically more expensive than EEG and studies are limited by issues of replication, sometimes that is related to head motion that occurred during the scan which can erode signal 61”
From Autism spectrum disorder (2020) · cites this paper as [61]
In the citing paper
“Especially considering the ability of the recombinant AAV genome to persist as an episome in post-mitotic cells, such as neurons, which ensures long-term expression even after a single administration [130-132].”
From Circumventing the packaging limit of AAV-mediated gene replacement therapy for neurological disorders (2022) · cites this paper as [132]
In the citing paper
“With AAV9’s inherent ability to target motor neurons, AAV9-based Zolgensma® for the treatment of SMA has been established as the first FDA-approved drug for systemic gene therapy in CNS diseases [171].”
From Designing and optimizing AAV-mediated gene therapy for neurodegenerative diseases: from bench to bedside (2024) · cites this paper as [171]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
1 retracted
Foust, K. D., Wang, X., McGovern, V. L., Braun, L., Bevan, A. K., Haidet, A. M., Le, T. T., Morales, P. R., Rich, M. M., Burghes, A. H. M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1610 · Cited by 688
Self-citationRetractedDeaths: preliminary data for 2003.
Hoyert, D. L., Kung, H.-C., & Smith, B. L. (2005) · PubMed · Cited by 1,649
Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes
Foust, K. D., Nurre, E., Montgomery, C. L., Hernandez, A., Chan, C. M., & Kaspar, B. K. (2009) · Nature Biotechnology · doi:10.1038/nbt.1515 · Cited by 1,456
Self-citationBayley Scales of Infant and Toddler Development, Third Edition
Bayley, N. (2012) · PsycTESTS Dataset · doi:10.1037/t14978-000 · Cited by 1,175
National Vital Statistics Reports NCHS.pdf
Hoyert, D. (2012) · Medical Entomology and Zoology · Cited by 982
Consensus Statement for Standard of Care in Spinal Muscular Atrophy
Wang, C. H., Finkel, R. S., Bertini, E. S., Schroth, M., Simonds, A., Wong, B., Aloysius, A., Morrison, L., Main, M., Crawford, T. O., et al. (2007) · Journal of Child Neurology · doi:10.1177/0883073807305788 · Cited by 961 · cited 4×
“Viral upper respiratory tract infection 0 0 3 3 (25) 3 3 (20)”
InfluentialAntisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
Hua, Y., Sahashi, K., Hung, G., Rigo, F., Passini, M. A., Bennett, C. F., & Krainer, A. R. (2010) · Genes & Development · doi:10.1101/gad.1941310 · Cited by 664
Sugarman, E. A., Nagan, N., Zhu, H., Akmaev, V. R., Zhou, Z., Rohlfs, E. M., Flynn, K., Hendrickson, B. C., Scholl, T., Sirko-Osadsa, D. A., et al. (2012) · European Journal of Human Genetics · doi:10.1038/ejhg.2011.134 · Cited by 661
Passini, M. A., Bu, J., Richards, A. M., Kinnecom, C., Sardi, S. P., Stanek, L. M., Hua, Y., Rigo, F., Matson, J., Hung, G., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001777 · Cited by 547
de Onis, M., Onyango, A. W., Van den Broeck, J., Chumlea, W. C., & Martorell, R. (2004) · Food and Nutrition Bulletin · doi:10.1177/15648265040251s105 · Cited by 529
Research works printed but not linked: 1
- Hoyert DL, 2012, Natl Vital Stat Rep, 61, 1
Cited by
Items 101–200 of 1,005
Al-Zaidy, S. A., Kolb, S. J., Lowes, L., Alfano, L. N., Shell, R., Church, K. R., Nagendran, S., Sproule, D. M., Feltner, D. E., Wells, C., et al. (2019) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-190403 · Cited by 185
“In a phase 1 80 trial, the AVXS-101 study, all participants receiving 81 a 1-time intravenous dose of AVXS-101 achieved per82 manent ventilation-free survival up to 24 months of 83 age and further [10, 11].”
InfluentialSelf-citationCRISPR Correction of Duchenne Muscular Dystrophy
Min, Y.-L., Bassel-Duby, R., & Olson, E. N. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-081117-010451 · Cited by 183
“Indeed, the FDA has approved AAV for gene replacement therapy in spinal muscular atrophy, and clinical trials are in progress (91).”
BackgroundAl-Zaidy, S. A., & Mendell, J. R. (2019) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2019.06.007 · Cited by 182
Self-citationLowes, L. P., Alfano, L. N., Arnold, W. D., Shell, R., Prior, T. W., McColly, M., Lehman, K. J., Church, K., Sproule, D. M., Nagendran, S., et al. (2019) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2019.05.005 · Cited by 179
Self-citationSpinal Muscular Atrophy: In the Challenge Lies a Solution
Wirth, B. (2021) · Trends in Neurosciences · doi:10.1016/j.tins.2020.11.009 · Cited by 177
Newborn screening programs for spinal muscular atrophy worldwide: Where we stand and where to go
Dangouloff, T., Vrščaj, E., Servais, L., Osredkar, D., Adoukonou, T., Aryani, O., Barisic, N., Bashiri, F., Bastaki, L., Benitto, A., et al. (2021) · Neuromuscular Disorders · doi:10.1016/j.nmd.2021.03.007 · Cited by 176
Bak, R. O., Gomez-Ospina, N., & Porteus, M. H. (2018) · Trends in Genetics · doi:10.1016/j.tig.2018.05.004 · Cited by 176
Drug delivery systems for CRISPR-based genome editors
Madigan, V., Zhang, F., & Dahlman, J. E. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00762-x · Cited by 172
“Given that Zolgensma effectively treats an otherwise fatal disease 42,123 , patients are likely to tolerate these side effects; however, this conclusion may not be true for mild diseases.”
BackgroundDuchenne muscular dystrophy: disease mechanism and therapeutic strategies
Bez Batti Angulski, A., Hosny, N., Cohen, H., Martin, A. A., Hahn, D., Bauer, J., & Metzger, J. M. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1183101 · Cited by 173
“, 2019a), and clinical trials using AAV for gene replacement therapy have been approved by the FDA (Mendell et al., 2017).”
InfluentialrAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis
Shen, W., Liu, S., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1001263 · Cited by 173
“Another 6 trials are associated with Zolgensma, which uses self-complementary AAV9 and have been approved as a commercialized product (35).”
BackgroundInfluentialNusinersen treatment of spinal muscular atrophy: current knowledge and existing gaps
Gidaro, T., & Servais, L. (2019) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.14027 · Cited by 144
“The goals of these therapies are either to increase production of fulllength SMN2 protein expression by interfering with the spliceosome(27) or to express SMN from an exogenous gene copy delivered through viral transfection.(28) Data are promising, but the only clinical report published so far(26) was monocentric and,…”
BackgroundSpinal Muscular Atrophy: Mutations, Testing, and Clinical Relevance
Keinath, M. C., Prior, D. E., & Prior, T. W. (2021) · The Application of Clinical Genetics · doi:10.2147/tacg.s239603 · Cited by 170
Self-citationPost-translational modifications in liquid-liquid phase separation: a comprehensive review
Li, J., Zhang, M., Ma, W., Yang, B., Lu, H., Zhou, F., & Zhang, L. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00075-2 · Cited by 171
Rapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning
Nonnenmacher, M., Wang, W., Child, M. A., Ren, X.-Q., Huang, C., Ren, A. Z., Tocci, J., Chen, Q., Bittner, K., Tyson, K., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.12.006 · Cited by 168
Polygenic architecture of rare coding variation across 394,783 exomes
Weiner, D. J., Nadig, A., Jagadeesh, K. A., Dey, K. K., Neale, B. M., Robinson, E. B., Karczewski, K. J., & O’Connor, L. J. (2023) · Nature · doi:10.1038/s41586-022-05684-z · Cited by 165
Chaytow, H., Faller, K. M. E., Huang, Y.-T., & Gillingwater, T. H. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100346 · Cited by 165
“This first trial treated 15 infants, 3 with low dose and 12 with high dose: all 15 patients survived to 20 months without the need for respiratory support, with 11 patients reaching the motor milestone of sitting unassisted and 2 even walking independently.(35) This positive phase I trial and interim data released fro…”
BackgroundStructural basis of a small molecule targeting RNA for a specific splicing correction
Campagne, S., Boigner, S., Rüdisser, S., Moursy, A., Gillioz, L., Knörlein, A., Hall, J., Ratni, H., Cléry, A., & Allain, F. H.-T. (2019) · Nature Chemical Biology · doi:10.1038/s41589-019-0384-5 · Cited by 162
Newborn screening for spinal muscular atrophy in Germany: clinical results after 2 years
Vill, K., Schwartz, O., Blaschek, A., Gläser, D., Nennstiel, U., Wirth, B., Burggraf, S., Röschinger, W., Becker, M., Czibere, L., et al. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-01783-8 · Cited by 164
Nusinersen: A Novel Antisense Oligonucleotide for the Treatment of Spinal Muscular Atrophy
Neil, E. E., & Bisaccia, E. K. (2019) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-24.3.194 · Cited by 162
Characterization and mitigation of gene expression burden in mammalian cells
Frei, T., Cella, F., Tedeschi, F., Gutiérrez, J., Stan, G.-B., Khammash, M., & Siciliano, V. (2020) · Nature Communications · doi:10.1038/s41467-020-18392-x · Cited by 161
Fetal gene therapy for neurodegenerative disease of infants
Massaro, G., Mattar, C. N. Z., Wong, A. M. S., Sirka, E., Buckley, S. M. K., Herbert, B. R., Karlsson, S., Perocheau, D. P., Burke, D., Heales, S., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0106-7 · Cited by 161
Zhang, Y., Li, H., Min, Y.-L., Sanchez-Ortiz, E., Huang, J., Mireault, A. A., Shelton, J. M., Kim, J., Mammen, P. P. A., Bassel-Duby, R., et al. (2020) · Science Advances · doi:10.1126/sciadv.aay6812 · Cited by 161
Overturning the Paradigm of Spinal Muscular Atrophy as Just a Motor Neuron Disease
Yeo, C. J. J., & Darras, B. T. (2020) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2020.01.003 · Cited by 159
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer
Arjomandnejad, M., Dasgupta, I., Flotte, T. R., & Keeler, A. M. (2023) · BioDrugs · doi:10.1007/s40259-023-00585-7 · Cited by 159
“Zolgensma was able to achieve clinically relevant therapeutic outcomes and has attained promising results in reducing premature death in SMA patients [141, 142].”
BackgroundSalabarria, S. M., Corti, M., Coleman, K. E., Wichman, M. B., Berthy, J. A., D’Souza, P., Tifft, C. J., Herzog, R. W., Elder, M. E., Shoemaker, L. R., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci173510 · Cited by 159
“A previous in vitro study showed that complement activation is observed with all adenovirus serotypes tested, including serotypes 1, 3, 4, and 9 (39).”
BackgroundKaufmann, P., Pariser, A., & Austin, C. P. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0936-x · Cited by 169
Gene Therapy Tools for Brain Diseases
Ingusci, S., Verlengia, G., Soukupova, M., Zucchini, S., & Simonato, M. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00724 · Cited by 158
“To increase the safety of lentiviral vectors, the viral genome can be split in multiple plasmids, thereby making recombinant virus generation very unlikely (Milone and O’Doherty, 2018).”
BackgroundSpinal Muscular Atrophy: The Past, Present, and Future of Diagnosis and Treatment
Nishio, H., Niba, E. T. E., Saito, T., Okamoto, K., Takeshima, Y., & Awano, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241511939 · Cited by 202
“By contrast, there was little improvement in the motor function of patients who were treated after 3 months of age or had low motor function (CHOP INTEND score of <20 points) at the time of treatment, even if they were in the high-dose cohort [141,142].”
BackgroundMethodNew Treatments in Spinal Muscular Atrophy: Positive Results and New Challenges
Messina, S., & Sframeli, M. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9072222 · Cited by 179
Public Acceptability of Gene Therapy and Gene Editing for Human Use: A Systematic Review
Delhove, J. M. K. M., Osenk, I., Prichard, I. J., & Donnelley, M. (2019) · Human Gene Therapy · doi:10.1089/hum.2019.197 · Cited by 165
“…severe combined im-munodeficiency (SCID), 3 hemophilia, 4 Wiskott–Aldrich syndrome, 5 metachromatic leukodystrophy, 6 spinal mus-* cular atrophy, 7 and CF. 8,9 Recently, Luxturna (Spark Therapeutics) became the first Food and Drug Administration (FDA)-approved prescription gene therapy, treating…”
Coratti, G., Cutrona, C., Pera, M. C., Bovis, F., Ponzano, M., Chieppa, F., Antonaci, L., Sansone, V., Finkel, R. S., Pane, M., et al. (2021) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-021-02065-z · Cited by 170
Selection of an Efficient AAV Vector for Robust CNS Transgene Expression
Hanlon, K. S., Meltzer, J. C., Buzhdygan, T., Cheng, M. J., Sena-Esteves, M., Bennett, R. E., Sullivan, T. P., Razmpour, R., Gong, Y., Ng, C., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.10.007 · Cited by 148
Adeno-Associated Virus Toolkit to Target Diverse Brain Cells
Challis, R. C., Ravindra Kumar, S., Chen, X., Goertsen, D., Coughlin, G. M., Hori, A. M., Chuapoco, M. R., Otis, T. S., Miles, T. F., & Gradinaru, V. (2022) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-111020-100834 · Cited by 148
“US Food and Drug Administration approvals of Luxturna for RPE65 -associated retinal dystrophy (Russell et al. 2017) and Zolgensma for spinal muscular atrophy (Mendell et al. 2017) demonstrate that AAV-based therapies can be effective in the CNS (Zhu et al. 2021).”
BackgroundNext-generation AAV vectors—Do not judge a virus (only) by its cover
Domenger, C., & Grimm, D. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddz148 · Cited by 147
Autism Spectrum Disorder Genetics and the Search for Pathological Mechanisms
Manoli, D. S., & State, M. W. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20111608 · Cited by 146
Gene therapy targeting SARM1 blocks pathological axon degeneration in mice
Geisler, S., Huang, S. X., Strickland, A., Doan, R. A., Summers, D. W., Mao, X., Park, J., DiAntonio, A., & Milbrandt, J. (2019) · Journal of Experimental Medicine · doi:10.1084/jem.20181040 · Cited by 145
Recent progress and considerations for AAV gene therapies targeting the central nervous system
Lykken, E. A., Shyng, C., Edwards, R. J., Rozenberg, A., & Gray, S. J. (2018) · Journal of Neurodevelopmental Disorders · doi:10.1186/s11689-018-9234-0 · Cited by 143
“Recently, intravenous treatment with an AAV9 vector in an ongoing clinical trial for SMA1 demonstrated dramatic improvements in motor development and survival [63].”
BackgroundInak, G., Rybak-Wolf, A., Lisowski, P., Pentimalli, T. M., Jüttner, R., Glažar, P., Uppal, K., Bottani, E., Brunetti, D., Secker, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22117-z · Cited by 145
Durability of transgene expression after rAAV gene therapy
Muhuri, M., Lévy, D., Schulz, M., McCarty, D. M., & Gao, G. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.03.004 · Cited by 172
“Similarly, T cell responses have been identified in clinical trials for neuromuscular disorders, although not always with a corresponding loss of expression.(104,105)”
BackgroundShieh, P. B., Kuntz, N. L., Dowling, J. J., Müller‐Felber, W., Bönnemann, C. G., Seferian, A., Servais, L., Smith, B. K., Muntoni, F., Blaschek, A., et al. (2023) · The Lancet Neurology · doi:10.1016/s1474-4422(23)00313-7 · Cited by 162
“With the exception of the deaths related to hepatobiliary disease, most adverse events in dosed participants were consistent with those reported in patients who received other AAV-based gene therapy products, 14,41,42 including transient thrombocytopenia and troponin elevation.”
ResultSelf-citationAAV gene therapy for Tay-Sachs disease
Flotte, T. R., Cataltepe, O., Puri, A., Batista, A. R., Moser, R., McKenna-Yasek, D., Douthwright, C., Gernoux, G., Blackwood, M., Mueller, C., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01664-4 · Cited by 143
Bezzerides, V. J., Caballero, A., Wang, S., Ai, Y., Hylind, R. J., Lu, F., Heims-Waldron, D. A., Chambers, K. D., Zhang, D., Abrams, D. J., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038514 · Cited by 151
Chen, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093297 · Cited by 165
“The first AAV9-SMN1 gene therapy, Zolgensma (AVXS-101 or onasemnogene abeparvovec), was administered in 15 type 1 SMA patients, and showed a significant improvement in motor and survival in a phase 1/2a trial [39].”
MethodImmunogenicity of CRISPR therapeutics—Critical considerations for clinical translation
Ewaisha, R., & Anderson, K. S. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1138596 · Cited by 165
“Corticosteroids are approved for use with two AAV-based gene therapy drugs in clinical use, Zolgensma (Mendell et al., 2017) and Luxturna (Russell et al., 2017).”
BackgroundMethodBase editing rescue of spinal muscular atrophy in cells and in mice
Arbab, M., Matuszek, Z., Kray, K. M., Du, A., Newby, G. A., Blatnik, A. J., Raguram, A., Richter, M. F., Zhao, K. T., Levy, J. M., et al. (2023) · Science · doi:10.1126/science.adg6518 · Cited by 139
“Upregulation of SMN protein levels improves motor function and life expectancy of SMA patients and animal models if achieved prior to onset of neuromuscular pathology and symptoms(13, 32, 86-88, 93), yet even high levels of SMN protein cannot correct neuromuscular junction defects once SMA has progressed to an advance…”
BackgroundInfluentialSelf-citationSpinal muscular atrophy diagnosis and carrier screening from genome sequencing data
Chen, X., Sanchis-Juan, A., French, C. E., Connell, A. J., Delon, I., Kingsbury, Z., Chawla, A., Halpern, A. L., Taft, R. J., Bentley, D. R., et al. (2020) · Genetics in Medicine · doi:10.1038/s41436-020-0754-0 · Cited by 137
“SMN2 CN has been used as a criterion for many clinical trials for SMA, including nusinersen(8) and Zolgensma.(9)”
MethodSubacute Liver Failure Following Gene Replacement Therapy for Spinal Muscular Atrophy Type 1
Feldman, A. G., Parsons, J. A., Dutmer, C. M., Veerapandiyan, A., Hafberg, E., Maloney, N., & Mack, C. L. (2020) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2020.05.044 · Cited by 136
GPR108 Is a Highly Conserved AAV Entry Factor
Dudek, A. M., Zabaleta, N., Zinn, E., Pillay, S., Zengel, J., Porter, C., Franceschini, J. S., Estelien, R., Carette, J. E., Zhou, G. L., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.005 · Cited by 132
“AAV-based gene therapies have demonstrated great success in clinical trials and more recently in the US Food and Drug Administration (FDA) approval of a gene therapy for an inherited type of blindness(5) and a form of spinal muscular atrophy.(3) Remarkably, how this family of viruses enters cells to efficiently delive…”
Cheung, A. K., Hurley, B., Kerrigan, R., Shu, L., Chin, D. N., Shen, Y., O’Brien, G., Sung, M. J., Hou, Y., Axford, J., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01291 · Cited by 142
Acid ceramidase deficiency: Farber disease and SMA-PME
Yu, F. P. S., Amintas, S., Levade, T., & Medin, J. A. (2018) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-018-0845-z · Cited by 143
“While the trial is still ongoing, preliminary data demonstrate a reduced need for pulmonary support, and patients could feed themselves, indicating a potential improvement in swallowing function [182, 183].”
BackgroundPriddy, F. H., Lewis, D. J. M., Gelderblom, H. C., Hassanin, H., Streatfield, C., LaBranche, C., Hare, J., Cox, J. H., Dally, L., Bendel, D., et al. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30003-7 · Cited by 131
AAV vectors applied to the treatment of CNS disorders: Clinical status and challenges
Kang, L., Jin, S., Wang, J., Lv, Z., Xin, C., Tan, C., Zhao, M., Wang, L., & Liu, J. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.01.067 · Cited by 131
Antisense oligonucleotides in neurological disorders
Wurster, C. D., & Ludolph, A. C. (2018) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756286418776932 · Cited by 146
The promise of microRNA-based therapies in Alzheimer’s disease: challenges and perspectives
Walgrave, H., Zhou, L., De Strooper, B., & Salta, E. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00496-7 · Cited by 131
“Bringing microRNA therapeutics into the clinical practice: hurdles and challenges Federal Drug Agency (FDA)-approved drugs for AD include cholinesterase inhibitors, memantine and just very recently, also the first disease-modifying drug, the monoclonal antibody aducanumab, which has been shown to lower Aβ levels [20,…”
BackgroundMethodInfluentialAcoustically targeted chemogenetics for the non-invasive control of neural circuits
Szablowski, J. O., Lee‐Gosselin, A., Lue, B., Malounda, D., & Shapiro, M. G. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0258-2 · Cited by 132
Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes
Waldrop, M. A., Karingada, C., Storey, M. A., Powers, B., Iammarino, M. A., Miller, N. F., Alfano, L. N., Noritz, G., Rossman, I., Ginsberg, M., et al. (2020) · Pediatrics · doi:10.1542/peds.2020-0729 · Cited by 130
“However, the approval of 2 therapies since late 2016 has markedly changed the course of this disease.(5,6)”
BackgroundMethodResultSelf-citationRyanodine Receptor 1-Related Myopathies: Diagnostic and Therapeutic Approaches
Lawal, T. A., Todd, J. J., & Meilleur, K. G. (2018) · Neurotherapeutics · doi:10.1007/s13311-018-00677-1 · Cited by 138
“As such, gene therapy approaches, such as those that have shown great promise for spinal muscular atrophy [97], are not currently feasible for RYR1RM.”
BackgroundNew treatments in spinal muscular atrophy: an overview of currently available data
Ramdas, S., & Servais, L. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1704732 · Cited by 142
“Pre-clinical studies demonstrated SMN expression in motor neurons and peripheral tissues in a mouse model of SMA with a significant extension of life span in mice followed 250 days [16,48].”
BackgroundRNA-binding proteins in neurological development and disease
Prashad, S., & Gopal, P. P. (2020) · RNA Biology · doi:10.1080/15476286.2020.1809186 · Cited by 128
“tional approaches to increase functional SMN are being investigated in preclinical studies [68].”
BackgroundCurrent clinical applications of AAV-mediated gene therapy
Byrne, B. J., Flanigan, K. M., Matesanz, S. E., Finkel, R. S., Waldrop, M. A., D'Ambrosio, E. S., Johnson, N. E., Smith, B. K., Bönnemann, C. G., Carrig, S., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.045 · Cited by 166
“57 This vector crosses the blood-brain barrier and can therefore be administered intravenously as a single dose.”
Sestan, N., & State, M. W. (2018) · Neuron · doi:10.1016/j.neuron.2018.10.015 · Cited by 127
Epilepsy Gene Therapy Using an Engineered Potassium Channel
Snowball, A., Chabrol, E., Wykes, R. C., Shekh-Ahmad, T., Cornford, J. H., Lieb, A., Hughes, M. P., Massaro, G., Rahim, A. A., Hashemi, K. S., et al. (2019) · The Journal of Neuroscience · doi:10.1523/jneurosci.1143-18.2019 · Cited by 127
Impaired prenatal motor axon development necessitates early therapeutic intervention in severe SMA
Kong, L., Valdivia, D. O., Simon, C. M., Hassinan, C. W., Delestrée, N., Ramos, D. M., Park, J. H., Pilato, C. M., Xu, X., Crowder, M. E., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb6871 · Cited by 140
SMArtCARE - A platform to collect real-life outcome data of patients with spinal muscular atrophy
Pechmann, A., König, K., Bernert, G., Schachtrup, K., Schara, U., Schorling, D., Schwersenz, I., Stein, S., Tassoni, A., Vogt, S., et al. (2019) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-019-0998-4 · Cited by 144
A framework for the investigation of rare genetic disorders in neuropsychiatry
Sanders, S. J., Sahin, M., Hostyk, J., Thurm, A., Jacquemont, S., Avillach, P., Douard, E., Martin, C. L., Modi, M. E., Moreno-De-Luca, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0581-5 · Cited by 123
Inhibition of RNA-binding proteins with small molecules
Wu, P. (2020) · Nature Reviews Chemistry · doi:10.1038/s41570-020-0201-4 · Cited by 146
The Role of RNA Binding Proteins for Local mRNA Translation: Implications in Neurological Disorders
Thelen, M. P., & Kye, M. J. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00161 · Cited by 133
“As SMA is caused by deficiency of SMN protein, SMN protein can be restored in motor neurons by viral delivery (Mendell et al., 2017).”
BackgroundMendell, J. R., Connolly, A. M., Lehman, K. J., Griffin, D. A., Khan, S. Z., Dharia, S. D., Quintana-Gallardo, L., & Rodino-Klapac, L. R. (2022) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2022.02.011 · Cited by 124
Self-citationWeiß, C., Ziegler, A., Becker, L.-L., Johannsen, J., Brennenstuhl, H., Schreiber, G., Flotats-Bastardas, M., Stoltenburg, C., Hartmann, H., Illsinger, S., et al. (2021) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(21)00287-x · Cited by 132
Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets
Taghdiri, M., & Mussolino, C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137333 · Cited by 145
“A similar path has been followed for the treatment of spinal muscular atrophy, in which the success of AAV9-based gene therapy to replace the defective Survival of Motor Neuron 1 ( SMN1 ) gene in motor neurons was ultimately approved as a therapy under the name Zolgensma (Table 3) [89].”
BackgroundJourney to the Center of the Cell: Tracing the Path of AAV Transduction
Dhungel, B. P., Bailey, C. G., & Rasko, J. E. J. (2021) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2020.09.010 · Cited by 122
Fibroblast Growth Factor Signalling in the Diseased Nervous System
Klimaschewski, L., & Claus, P. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02367-0 · Cited by 120
Pompe disease: pathogenesis, molecular genetics and diagnosis
Taverna, S., Cammarata, G., Colomba, P., Sciarrino, S., Zizzo, C., Francofonte, D., Zora, M., Scalia, S., Brando, C., Curto, A. L., et al. (2020) · Aging · doi:10.18632/aging.103794 · Cited by 146
“One limitation of the systemic route to target muscles is the use of high doses of vector [111].”
BackgroundGriciuc, A., Federico, A. N., Natasan, J., Forte, A. M., McGinty, D., Nguyen, H., Volak, A., LeRoy, S., Gandhi, S., Lerner, E. P., et al. (2020) · Human Molecular Genetics · doi:10.1093/hmg/ddaa179 · Cited by 121
“AAV vectors have made impressive progress for in vivo gene therapy including for treatment of CNS diseases such as spinal muscular atrophy (SMA) in infants (25).”
BackgroundPreventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases
Benatar, M. G., Wuu, J., McHutchison, C. A., Postuma, R. B., Boeve, B. F., Petersen, R. C., Ross, C. A., Rosen, H. J., Arias, J. J., Fradette, S., et al. (2021) · Brain · doi:10.1093/brain/awab404 · Cited by 133
“Interventional studies in pre-symptomatic individuals have demonstrated efficacy far beyond what has been observed from the same treatment in post-symptomatic individuals.(76,80,82,83) These data may inform other neurodegenerative diseases in which a pre-symptomatic or prodromal phase can be identified to trigger earl…”
Corti, M., Liberati, C., Smith, B. K., Lawson, L. A., Tuna, I. S., Conlon, T. J., Coleman, K. E., Islam, S., Herzog, R. W., Fuller, D. D., et al. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.146 · Cited by 120
“The study has confirmed a favorable safety profile, with no treatment-related safety or tolerability concerns identified, as well as important findings of efficacy.(80) An additional study of systemic AAV9 for MSP IIIA is underway with favorable results thus far (NCT02716246).”
BackgroundMeganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol
Wang, L., Smith, J., Breton, C. A., Clark, P., Zhang, J., Lei, Y., Che, Y., Lape, J., Bell, P. L., Calcedo, R., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4182 · Cited by 127
Yao, Y., Wang, J., Liu, Y., Qu, Y., Wang, K., Zhang, Y., Chang, Y., Yang, Z., Wan, J., Liu, J., et al. (2022) · Nature Biomedical Engineering · doi:10.1038/s41551-022-00938-7 · Cited by 120
Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
Day, J. W., Mendell, J. R., Mercuri, E., Finkel, R. S., Strauss, K. A., Kleyn, A., Tauscher-Wisniewski, S., Tukov, F. F., Reyna, S. P., & Chand, D. H. (2021) · Drug Safety · doi:10.1007/s40264-021-01107-6 · Cited by 119
Self-citationAdeno-Associated Viral Vectors in Neuroscience Research
Haggerty, D. L., Grecco, G. G., Reeves, K. C., & Atwood, B. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.11.012 · Cited by 118
“Spinal muscular atrophy (SMA), the most common genetic cause of death in infants, results from a loss or dysfunction in the survival motor neuron (SMN1) gene.(118) The disease results in progressive loss of lower motor neurons and muscle atrophy, often leading to respiratory failure.”
BackgroundResultInfluentialNatural history of Type 2 and 3 spinal muscular atrophy: 2‐year NatHis‐SMA study
Annoussamy, M., Seferian, A., Daron, A., Péréon, Y., Cancés, C., Vuillerot, C., Waele, L. D., Laugel, V., Schara, U., Gidaro, T., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51281 · Cited by 136
“These therapies have demonstrated improvements in survival and motor function;(12) however, the long-term efficacy of these treatments remains unknown, and access may be restricted by SMA type.(13) Therefore, there is a clear need to identify reliable outcome measures for different stages in SMA progression so that th…”
BackgroundSelf-citationBey, K., Deniaud, J., Dubreil, L., Joussemet, B., Cristini, J., Ciron, C., Hordeaux, J., Le Boulc’h, M., Marche, K., Maquigneau, M., et al. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.04.001 · Cited by 116
Feng, G., Jensen, F. E., Greely, H. T., Okano, H., Treue, S., Roberts, A. C., Fox, J. G., Caddick, S., Poo, M.-M., Newsome, W. T., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2006515117 · Cited by 117
Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions
Riyad, J. M., & Weber, T. (2021) · Gene Therapy · doi:10.1038/s41434-021-00243-z · Cited by 118
Immunogenicity assessment of AAV-based gene therapies: An IQ consortium industry white paper
Yang, T., Braun, M., Lembke, W., McBlane, F., Kamerud, J., DeWall, S. L., Tarcsa, E., Fang, X., Hofer, L., Kavita, U., et al. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.07.018 · Cited by 136
Biodistribution of onasemnogene abeparvovec DNA, mRNA and SMN protein in human tissue
Thomsen, G. M., Burghes, A. H. M., Hsieh, C., Do, J., Chu, B. T. T., Perry, S., Barkho, B. Z., Kaufmann, P., Sproule, D. M., Feltner, D. E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01483-7 · Cited by 123
Self-citationDisease-modifying therapies in amyotrophic lateral sclerosis
Chiò, A., Mazzini, L., & Mora, G. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107986 · Cited by 115
Gene therapy beyond luxturna: a new horizon of the treatment for inherited retinal disease
Prado, D. A., Acosta-Acero, M., & Maldonado, R. S. (2020) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000660 · Cited by 114
“This AAV vector-based gene therapy is a one-time intravenous injection that delivers a fully-functional copy of the SMN gene into the target motor neuron cells [12].”
BackgroundTordo, J., O’Leary, C., Antunes, A. S. L. M., Palomar, N., Aldrin-Kirk, P., Basche, M., Bennett, A., D’Souza, Z., Gleitz, H., Godwin, A., et al. (2018) · Brain · doi:10.1093/brain/awy126 · Cited by 113
“However, despite recent unparalleled results in an AAV gene therapy trial for spinal muscular atrophy (Mendell et al., 2017), other AAV gene therapies directed at the brain of patients with rare neurological diseases have shown only limited efficacy (Worgall et al.”
Blesa, J., Pineda‐Pardo, J. A., Inoue, K., Gasca‐Salas, C., Balzano, T., del Rey, N. L., Reinares-Sebastián, A., Esteban-García, N., Rodríguez‐Rojas, R., Márquez, R., et al. (2023) · Science Advances · doi:10.1126/sciadv.adf4888 · Cited by 121
Perez, B. A., Shutterly, A., Chan, Y. K., Byrne, B. J., & Corti, M. (2020) · Brain Sciences · doi:10.3390/brainsci10020119 · Cited by 112
“Similarly, several preclinical studies and clinical trials [5,42] evaluated safety and efficacy data with no significant findings in support of the U.”
BackgroundImmune-evasive gene switch enables regulated delivery of chondroitinase after spinal cord injury
Burnside, E. R., De Winter, F., Didangelos, A., James, N. D., Andreica, E.-C., Layard-Horsfall, H., Muir, E. M., Verhaagen, J., & Bradbury, E. J. (2018) · Brain · doi:10.1093/brain/awy158 · Cited by 111
“neurodegenerative diseases (Mendell et al., 2017), where any”
Specific inhibition of myostatin activation is beneficial in mouse models of SMA therapy
Long, K. K., O’Shea, K. M., Khairallah, R. J., Howell, K., Paushkin, S., Chen, K. S., Cote, S. M., Webster, M. T., Stains, J. P., Treece, E., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddy382 · Cited by 112
Newborn screening for SMA in Southern Belgium
Boemer, F., Caberg, J., Dideberg, V., Dardenne, D., Bours, V., Hiligsmann, M., Dangouloff, T., & Servais, L. (2019) · Neuromuscular Disorders · doi:10.1016/j.nmd.2019.02.003 · Cited by 126
A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna
Taghian, T., Marosfoi, M. G., Puri, A. S., Cataltepe, O. I., King, R. M., Diffie, E. B., Maguire, A. S., Martin, D. R., Fernau, D., Batista, A. R., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.012 · Cited by 110
“with the recent approval of Zolgensma to treat spinal muscular atrophy.(12) Unfortunately, exceptional transduction appears to be limited to the spinal cord.”
BackgroundGene therapy: a double-edged sword with great powers
Tang, R., & Xu, Z. (2020) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-020-03834-3 · Cited by 134
Natural history of lung function in spinal muscular atrophy
Wijngaarde, C. A., Veldhoen, E. S., van Eijk, R. P. A., Stam, M., Otto, L. A. M., Asselman, F., Asperen, R. M. W., Hulzebos, E. H. J., den Oudenrijn, L. P. V., Bartels, B., et al. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01367-y · Cited by 112
Novel targeted therapies for Parkinson’s disease
Ntetsika, T., Papathoma, P.-E., & Markaki, I. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00279-2 · Cited by 106
Natural course of scoliosis and lifetime risk of scoliosis surgery in spinal muscular atrophy
Wijngaarde, C. A., Brink, R. C., de Kort, F. A. S., Stam, M., Otto, L. A. M., Asselman, F., Bartels, B., van Eijk, R. P. A., Sombroek, J., Cuppen, I., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007742 · Cited by 117
The neuroplastic brain: current breakthroughs and emerging frontiers
Gazerani, P. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149643 · Cited by 175
“One of the most well-documented clinical cases is the approval of gene therapy for Spinal Muscular Atrophy (SMA) using onasemnogene abeparvovec (Zolgensma ® ) (Mendell et al., 2017).”
Metadata
- Authors
- Mendell, J. R., Al-Zaidy, S., Shell, R., Arnold, W. D., Rodino-Klapac, L. R., Prior, T. W., Lowes, L., Alfano, L., Berry, K., Church, K., Kissel, J. T., Nagendran, S., L’Italien, J., Sproule, D. M., Wells, C., Cardenas, J. A., Heitzer, M. D., Kaspar, A., Corcoran, S., Braun, L., Likhite, S., Miranda, C., Meyer, K., Foust, K. D., Burghes, A. H. M., & Kaspar, B. K.
- Affiliations
- Abigail Wexner Research Institute (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-11-02
- Volume
- 377
- Issue
- 18
- Pages
- 1713-1722
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2765253110
- Cited by
- 2,381
- References
- 26
- Citations by year
- 2026: 205 · 2025: 232 · 2024: 292 · 2023: 270 · 2022: 289 · 2021: 347 · 2020: 298 · 2019: 246 · 2018: 172 · 2017: 16
- FWCI
- 115.14
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Nationwide Children's Hospital
- AveXis
- Research Institute, Nationwide Children's Hospital
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- spinal muscular atrophy type 1, gene replacement therapy, adeno-associated virus vectors, SMN1, motor function, motor milestones, survival, CHOP INTEND, aminotransferase elevation, prednisolone, treatment efficacy and safety
- MeSH terms
- Dependovirus, Female, Genetic Vectors, Humans, Infant, Infant, Newborn, Infusions, Intravenous, Liver Diseases, Male, Motor Skills, Respiration, Artificial, Spinal Muscular Atrophies of Childhood, Genetic Therapy, Cohort Studies, Nutritional Support, Disease-Free Survival, Survival of Motor Neuron 1 Protein, Historically Controlled Study
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.